MRC Clinical Trials Unit at UCL

What MRC Clinical Trials Unit at UCL does

The MRC Clinical Trials Unit at UCL, reconstituted in April 2026 as the UCL Innovative Clinical Trials Unit, is an academic clinical trials unit embedded within the Institute of Clinical Trials and Methodology at University College London. Founded in 1998/1999 with Medical Research Council underpinning funding, the Unit conducts large-scale international clinical trials and meta-analyses across three primary research areas: cancer (prostate, ovarian, kidney, gastroesophageal, blood), infections (HIV, tuberculosis, neonatal sepsis), and neurodegenerative diseases (multiple sclerosis, Parkinson's). Its flagship STAMPEDE trial has enrolled over 12,000 participants, tested 10 treatments, and changed prostate cancer standard-of-care four times across 18 years.

The Unit's core intellectual products are its adaptive trial design methodologies — Multi-Arm Multi-Stage (MAMS), PRACTical, Response-adaptive randomisation (ROCI), and the Framework for Adaptive Meta-analysis (FAME) — alongside Individual Participant Data (IPD) meta-analysis capability and open-source statistical implementations in Stata and R. These designs have been adopted globally to compress trial timelines and reduce costs. The Unit co-founded the ACORD collaboration for neurodegenerative MAMS trials and maintains capacity-strengthening programmes and a Patient and Public Involvement (PPI) group.

Commercially, the Unit does not sell products or services. It was funded by direct MRC underpinning grant from 1998 until March 2026, when MRC ended that funding model. In February 2026, the £50m MRC Centre of Research Excellence in Clinical Trial Innovation opened, led by Professor Mahesh Parmar with Deputy Directors Professors James Carpenter, Ruth Langley, and Ian White, providing a new public funding vehicle. Professor Angela Meade leads the reconstituted Unit from April 2026. Headcount stands at 72, with headquarters at 90 High Holborn, London, and active trial operations across the UK, Sub-Saharan Africa, and Asia-Pacific (India).

Name

MRC Clinical Trials Unit at UCL

Legal name

UCL Innovative Clinical Trials Unit

Website

https://mrcctu.ucl.ac.uk

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

51–100 employees

Short description

The UCL Innovative Clinical Trials Unit (formerly MRC Clinical Trials Unit at UCL) is an academic trials unit within UCL that designs and conducts large international clinical trials and meta-analyses in cancer, infections, and neurodegenerative diseases, pioneering adaptive designs such as MAMS, PRACTical, FAME, and ROCI.

Ownership category

akta.pro rank

Product category

Clinical Trial Research Services

NAICS

Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Health Services (8000), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Analytics, Risk-Based Monitoring (RBM) & Quality Management (HLACAOAI)

Keywords

• Clinical trial design
• Adaptive trial methodology
• Cancer clinical research
• Meta-analysis services
• Neurodegenerative trials

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure

Revenue model

1. MRC Underpinning Funding: The Unit received underpinning funding from the Medical Research Council (MRC) since 1998. This funding ended in March 2026 due to changes in MRC's funding approach. The Unit has been reconstituted as UCL Innovative Clinical Trials Unit.
2. Centre of Research Excellence in Clinical Trial Innovation: Professor Mahesh (Max) Parmar is Director of the new MRC-funded Centre of Research Excellence in Clinical Trial Innovation, which opened in February 2026. The Innovative Clinical Trials Unit will capitalise on existing close links and common staff with this centre.

Distribution channels3 records

Marketing channels8 records

Core offering

The MRC Clinical Trials Unit at UCL is an academic clinical trials unit that designs, conducts, and analyses large-scale international clinical trials, alongside methodological research and Individual Participant Data (IPD) meta-analyses, focused on cancer, infectious diseases, and neurodegenerative diseases. It has pioneered several innovative trial designs (MAMS, PRACTical, FAME, ROCI) and makes its statistical methodology available as open-source software tools in Stata and R.

Product overview

The UCL Innovative Clinical Trials Unit (formerly MRC Clinical Trials Unit at UCL) is a research-focused organization that provides clinical trial methodology services rather than commercial products. Its offerings include innovative trial designs (MAMS, PRACTical, ROCI), meta-analysis frameworks (FAME, IPD), and open-source statistical software tools for Stata and R. The unit conducts large-scale international clinical trials across cancer, infections, neurodegenerative diseases, and HIV, with a focus on adaptive trial methodologies and capacity strengthening globally.

Differentiator

Problem solved

Functional benefit

Products and services

• Clinical Trial Design and Conduct Services End-to-end design, conduct, and analysis of large-scale international clinical trials, primarily in cancer, infectious diseases, and neurodegenerative diseases, delivered for research funders, sponsors, and academic collaborators.
• Multi-Arm Multi-Stage (MAMS) Trial Design A pioneering adaptive trial methodology that allows multiple treatments to be evaluated simultaneously within a single trial, with planned interim analyses enabling addition or dropping of arms.
• PRACTical Trial Design A pragmatic trial design methodology developed to support evaluation of treatments in routine clinical practice settings.
• Individual Participant Data (IPD) Meta-Analysis Methodology and conduct of individual participant data meta-analyses, synthesising individual-level data across multiple trials to provide more robust evidence for clinical decision-making.
• Framework for Adaptive Meta-analysis (FAME) A framework for adaptive meta-analysis that enables evidence synthesis to be updated as new trial data become available.
• ROCI Design A Response-Overlapping-Credible-Interval (ROCI) design methodology developed for comparing treatments where response profiles overlap.
• Statistical Software Tools (Stata and R) Open-source implementations of the unit's statistical methodology in Stata and R, made available to the clinical research community.

Quantifiable outcome

• Over 12,000 participants enrolled, 10 treatments tested, standard-of-care changed 4 times
• +4 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Centre of Research Excellence in Clinical Trial Innovation (CoRE)coreStrategic or Co-development Partner · 1 February 2026The MRC-funded Centre of Research Excellence in Clinical Trial Innovation opened in February 2026, led by Professor Mahesh (Max) Parmar as Director, with Professors James Carpenter, Ruth Langley and Ian White as Deputy Directors. The Innovative Clinical Trials Unit will capitalise on existing close links and common staff with this centre to drive forward its mission.
• University College London (UCL)coreStrategic or Co-development PartnerThe Unit operates within the Institute of Clinical Trials and Methodology at UCL. Professor Mahesh (Max) Parmar remains Director of the Institute. The Unit transitioned from MRC Clinical Trials Unit to UCL Innovative Clinical Trials Unit in April 2026 while maintaining its position within UCL's academic structure.
• ACORD Collaboration (ACORD Fellows Academy)coreStrategic or Co-development PartnerThe ACORD collaboration is a national initiative co-founded by the Unit for multi-arm multi-stage trials in neurodegenerative diseases. It represents a new era for clinical trials in this area and offers new hope to people affected by these conditions. The collaboration includes the ACORD Fellows Academy for training.
• NIHR Associate Principal Investigator (PI) SchememinorStrategic or Co-development PartnerCapacity strengthening programme under the National Institute for Health and Care Research (NIHR) to enhance skills of trial teams the Unit works with across the globe.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Birmingham Clinical Trials Unit: UK academic CTU running trials across multiple disease areas including cancer and chronic disease. Comparable to the UCL unit in academic CTU structure and broad therapeutic portfolio.
• Cambridge Clinical Trials Unit: UK academic CTU conducting trials across cancer, infections, and other diseases with an emphasis on methodology. Comparable to the UCL unit in academic CTU structure and multi-disease research focus.
• Liverpool Clinical Trials Centre: UK academic clinical trials centre running large, multi-centre trials with strong methodology support. Comparable to the UCL unit in academic CTU structure and operational scale of trial delivery.
• Edinburgh Clinical Trials Unit: UK academic CTU conducting clinical trials across multiple therapeutic areas with strong methodology grounding. Comparable to the UCL unit in academic CTU structure and emphasis on trial design.
• King's Clinical Trials Unit: UK academic CTU at King's College London running trials across mental health, neurology, and other areas. Comparable to the UCL unit in academic CTU structure and methodology-led trial execution.
• Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU): UK academic clinical trials unit specialising in cancer trials with strong methodology and statistical leadership. Highly comparable to the UCL unit in therapeutic focus (cancer), academic CTU structure, and methodology-driven mandate.
• Imperial Clinical Trials Unit: UK academic CTU delivering methodological research and clinical trials across diverse therapeutic areas. Comparable to the UCL unit in academic CTU structure and emphasis on trial design innovation.
• MRC Biostatistics Unit (University of Cambridge): Methodology-focused MRC research unit developing statistical methods for clinical trials and biomedical research. Comparable to the UCL unit's methodology research stream, including MAMS, FAME, and adaptive design work.
• Nottingham Clinical Trials Unit (NCTU): UK Clinical Research Collaboration-registered CTU conducting randomised trials across varied conditions. Comparable to the UCL unit in academic CTU structure and multi-disease research focus.
• University of Oxford Clinical Trials Research Unit: Major UK academic CTU running large-scale, multi-arm trials across multiple therapeutic areas. Comparable to the UCL unit in scope of clinical trial expertise, multi-disease portfolio, and academic CTU model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/innovativectu
• YouTubeyoutube.com/@innovative-ctu
• LinkedInlinkedin.com/company/mrc-clinical-trials-unit-at-ucl

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MRC Clinical Trials Unit at UCL